البلد: إسرائيل
اللغة: الإنجليزية
المصدر: Ministry of Health
THIOGUANINE
PERRIGO ISRAEL AGENCIES LTD, ISRAEL
L01BB03
TABLETS
THIOGUANINE 40 MG
PER OS
Required
EXCELLA GMBH & CO.KG., GERMANY
TIOGUANINE
TIOGUANINE
Acute nonlymphocytic leukemia.
2013-07-31
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986 The medicine is dispensed with a doctor’s prescription only LANVIS TABLETS 40 MG The active ingredient and its quantity: THIOGUANINE 40 MG A list of inactive ingredients is detailed in section 6. READ THE LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE AS IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep the leaflet. You may need to read it again. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor, nurse or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if it seems to you that signs of their ailment are similar. 1. WHAT IS THE MEDICINE INTENDED FOR? Lanvis is a medicine for treating acute nonlymphocytic leukemia. THERAPEUTIC GROUP: A cytotoxic medicine (also called chemotherapeutic) from the family of purine analogs. 2. BEFORE USING THE MEDICINE DO NOT USE THE MEDICINE IF: - You are sensitive (allergic) to thioguanine (the active ingredient) or to any of the other ingredients contained in the medicine (see section 6). - You are pregnant or breastfeeding. SPECIAL WARNINGS REGARDING USE OF THE MEDICINE BEFORE TREATMENT WITH LANVIS, CONSULT THE DOCTOR IF: ∙ You have been using the medicine for a prolonged period. Prolonged use may increase the risk of side effects, such as liver problems. ∙ You suffer from low levels of the thiopurine methyltransferase (TPMT) enzyme. ∙ You suffer from Lesch-Nyhan Syndrome – a rare hereditary condition caused by deficiency of HPRT (hypoxanthine- guanine-phosphoribosyltransferase). If you are uncertain if one of the above sections applies to you, please consult the doctor, nurse or pharmacist before taking Lanvis. IF YOU ARE TAKING OR HAVE RECENTLY TAKEN, OR THERE IS A CHANCE YOU MAY TAKE OTHER MEDICINES, INCLUDING NON-PRESCRIPTION MEDICINES, NUTRITIONAL SUPPLEMENTS, VITAMINS AND HERBAL SUPPLEMENTS, TELL THE DOCTOR OR PHARMACIST. In particular, inf اقرأ الوثيقة كاملة
_The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in _ _December 2016 _ SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT LANVIS TABLETS 40 MG 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 40 mg thioguanine BP per tablet. Excipients: This product contains lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lanvis 40 mg tablets are white to off–white tablet, round, biconvex scored and imprinting 'T40' on one side, without score and debossing on the other side. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. _ _ 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Thioguanine is indicated for the treatment of acute nonlymphocytic leukemia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The exact dose and duration of administration will depend on the nature and dosage of other cytotoxic drugs given in conjunction with thioguanine. Thioguanine is variably absorbed following oral administration and plasma levels may be reduced following emesis or intake of food. Thioguanine can be used at various stages of treatment in short term cycles. However it is not recommended for use during maintenance therapy or similar long-term continuous treatments due to the high risk of liver toxicity (see section 4.4). Page 1 of 9 _Adults _ _ _ The usual dosage of thioguanine is between 100 and 200 mg/m 2 body surface area, per day. _ _ _Paediatric population _ Similar dosages to those used in adults, with appropriate correction for body surface area, have been used. _Use in the elderly _ _ _ There are no specific dosage recommendations in elderly patients (See dosage in _ _ renal or hepatic impairment). Thioguanine has been used in various combination chemotherapy schedules in elderly patients with acute leukaemia at equivalent doses to those used in younger patients. _Dosage in renal or hepatic impairment _ Consideration should be given to reducing the dosage in patients اقرأ الوثيقة كاملة